Anjeanette Ormonde

It’s not magic -- it’s science. With KBI Biopharma’s SUREmAb™ solution, your mAb development moves faster and smarter. Get minimum titers of 4 g/L and up to 10g/L for your IgG monoclonal antibodies before process optimization and tox material in just 6.5 months from transfection—guaranteed. Built on the SUREtechnology Platform™, powered by Selexis®, that has enabled bringing over 110 mAbs to clinic and 7 to market. Set your mAb program on the fast track.

Derisking Biomanufacturing: Why A CDMO In Poland Might Be Your Secret Weapon As the U.S. government works to pass the BIOSECURE Act, which aims to the protect the IP of U.S. pharma companies, the EU is simultaneously seeking to increase innovation across the European biomanufacturing industry. Amid these cultural shifts, sponsors are considering the best global partnerships for their goals.

Building upon 30+ years of experience in Highly Potent API (HPAPI) and complex API production with continued investment and capacity expansion, MilliporeSigma is an industry leader and reliable CDMO partner with the expertise and capabilities to tackle the unique challenges of these powerful compounds and the most intricate and potent API projects.